Search - tctmd.com

Displaying 101 - 120 of 214

Sort: Relevancy | Date

News Daily News

SCAAR: Lower Risk of Early, Late Stent Thrombosis with Newer DES vs BMS in STEMI

Yael L. Maxwell

July 03, 2014

News Daily News

Un Estudio Pone de Manifiesto la Disparidad entre Resultados de Estudios Pre y Post-Comercialización sobre SLF

Caitlin E. Cox

June 13, 2014

News Daily News

Study Highlights Disparity Between Pre-, Postmarket Study Outcomes for DES

Caitlin E. Cox

June 13, 2014

News Industry News

Elixir Medical Announces Outstanding Long-term Clinical Results at EuroPCR for World’s Broadest Portfolio of Three CE Mark-approved Novolimus Eluting Coronary Intervention Systems

May 23, 2014

News Industry News

Micell Technologies Announces Clinical Data from MiStent SES Studies Will Be Presented at EuroPCR 2014

May 15, 2014

News Daily News

Cardiac Rehab Reduces Late Lumen Loss, Improves Risk Profile in Patients with Long Lesions

April 14, 2014

News Conference News ACC 2014

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Yael L. Maxwell

April 03, 2014

Presentation ACC 2014

The Zotarolimus-eluting Endeavor sprint stent in Uncertain DES candidates (ZEUS)

Presenter: M. Valgimigli

March 31, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Daily News

ZES Continue to Match EES in All Comers at 4 Years

March 13, 2014

News Daily News

Tras 4 Años, os SLZ siguen Equiparándose a los SLE en Ensayos de Pacientes No Seleccionados

March 13, 2014

News Daily News

Los Resultados SLF Varían según el Estado de la Diabetes y la Complejidad de la Lesión

Caitlin E. Cox

March 13, 2014

News Daily News

DES Outcomes Vary by Diabetes Status, Lesion Complexity

Caitlin E. Cox

March 13, 2014

News Daily News

4年数据显示ZES在所有方面均可媲美EES

March 13, 2014

News Daily News

Meta-analysis: Cumulative Stroke Higher with CABG vs. PCI; Late Stroke Comparable

Yael L. Maxwell

January 09, 2014

News Daily News

Los SLF de 1ª Generación son Menos Rentables que SMD + Rapamicina Oral a los 5 Años

January 06, 2014

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

News Conference News TCT 2013

OPTIMIZE: 3-Month DAPT Safe with ZES

October 31, 2013

News Industry News

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

October 31, 2013

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

Advertisement

SCAAR: Lower Risk of Early, Late Stent Thrombosis with Newer DES vs BMS in STEMI

Un Estudio Pone de Manifiesto la Disparidad entre Resultados de Estudios Pre y Post-Comercialización sobre SLF

Study Highlights Disparity Between Pre-, Postmarket Study Outcomes for DES

Elixir Medical Announces Outstanding Long-term Clinical Results at EuroPCR for World’s Broadest Portfolio of Three CE Mark-approved Novolimus Eluting Coronary Intervention Systems

Micell Technologies Announces Clinical Data from MiStent SES Studies Will Be Presented at EuroPCR 2014

Cardiac Rehab Reduces Late Lumen Loss, Improves Risk Profile in Patients with Long Lesions

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

The Zotarolimus-eluting Endeavor sprint stent in Uncertain DES candidates (ZEUS)

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

ZES Continue to Match EES in All Comers at 4 Years

Tras 4 Años, os SLZ siguen Equiparándose a los SLE en Ensayos de Pacientes No Seleccionados

Los Resultados SLF Varían según el Estado de la Diabetes y la Complejidad de la Lesión

DES Outcomes Vary by Diabetes Status, Lesion Complexity

4年数据显示ZES在所有方面均可媲美EES

Meta-analysis: Cumulative Stroke Higher with CABG vs. PCI; Late Stroke Comparable

Los SLF de 1ª Generación son Menos Rentables que SMD + Rapamicina Oral a los 5 Años

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

OPTIMIZE: 3-Month DAPT Safe with ZES

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content